Edgewise Therapeutics Inc’s recently made public that its Chief Scientific Officer Russell Alan J unloaded Company’s shares for reported $0.24 million on Feb 05 ’25. In the deal valued at $30.02 per share,8,015 shares were sold. As a result of this transaction, Russell Alan J now holds 14,863 shares worth roughly $0.41 million.
Then, Russell Alan J sold 1,200 shares, generating $36,153 in total proceeds. Upon selling the shares at $30.13, the Chief Scientific Officer now owns 14,863 shares.
Before that, KOCH KEVIN sold 8,636 shares. Edgewise Therapeutics Inc shares valued at $259,298 were divested by the President and CEO at a price of $30.03 per share. As a result of the transaction, KOCH KEVIN now holds 14,478 shares, worth roughly $0.4 million.
Scotiabank initiated its Edgewise Therapeutics Inc [EWTX] rating to a Sector outperform in a research note published on March 07, 2025; the price target was $50. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in late January with a ‘”a Hold”‘ rating. Evercore ISI began covering EWTX with “an Outperform” recommendation on November 22, 2024. Piper Sandler started covering the stock on March 07, 2024. It rated EWTX as “an Overweight”.
Price Performance Review of EWTX
On Monday, Edgewise Therapeutics Inc [NASDAQ:EWTX] saw its stock fall -1.71% to $27.53. Over the last five days, the stock has gained 7.83%. Edgewise Therapeutics Inc shares have risen nearly 3.11% since the year began. Nevertheless, the stocks have risen 61.94% over the past one year. While a 52-week high of $38.12 was reached on 02/06/25, a 52-week low of $14.90 was recorded on 01/13/25. SMA at 50 days reached $27.00, while 200 days put it at $24.94.
Levels Of Support And Resistance For EWTX Stock
The 24-hour chart illustrates a support level at 26.94, which if violated will result in even more drops to 26.36. On the upside, there is a resistance level at 28.06. A further resistance level may holdings at 28.60. The Relative Strength Index (RSI) on the 14-day chart is 53.67, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.50, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 38.20%. Stochastics %K at 71.03% indicates the stock is a holding.
The most recent change occurred on May 01, 2023 when Truist began covering the stock and recommended ‘”a Buy”‘ rating .
